Objectives. Tumor heterogeneity can be measured by quantifying variance of nuclear characteristics by image analysis. Heterogeneity of cell nuclear features correlated with increased local progression in prostate cancer. In the present study, the influence of tumor heterogeneity on prostate-specific antigen (PSA) recur rence after radical retropubic prostatectomy was analyzed and tumor heterogeneity was compared in pa tients with and without neoadjuvant hormonal therapy. Methods. Retrospectively, radical prostatectomy material of 44 patients without and 12 patients with neoad juvant hormonal treatment with a postoperative follow-up of at least 4 years was studied. Each prostatectomy specimen was systematically embedded in paraffin, and each tumor area within the prostate was marked and analyzed by an image analysis system for 32 nuclear features comprising nuclear shape, size, DNA content, and chromatin pattern. Several clinical features were available: preoperative serum PSA, hemoglo bin concentration, Karnofsky score, tumor stage, and Gleason score. Results. Increased tumor heterogeneity, as expressed by differences in karyometric values between tumor areas in nuclear shape and chromatin pattern within the tumor, was significantly correlated with earlier PSA recurrence rate. As compared with nonpretreated patients, hormonally pretreated specimens showed smaller and less heterogeneous tumors. In particular, chromatin pattern heterogeneity was decreased in patients who underwent preoperative hormonal treatment compared with patients who were not pretreated. However, decreased heterogeneity was accompanied by a higher percentage of aneuploid areas per tumor in the pretreated patients. Cox regression analysis showed that karyometric determination of nuclear shape heterogeneity in combination with preoperative PSA level could predict time to PSA recurrence after radical prostatectomy in patients without hormonal pretreatment. Conclusions. Increase in karyometric tumor heterogeneity in nuclear shape and chromatin pattern was cor related with a shorter PSA recurrence-free interval after radical prostatectomy. Preoperative PSA and kary ometric tumor heterogeneity were the best predictors of PSA recurrence in a multivariate analysis. Intratumoral heterogeneity was decreased in patients with prostate cancer who underwent neoadjuvant hormonal therapy. UROLOGY 49: 652-657, 1997.
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noma. Other studies, however, could not confirm this correlation with prognosis. 4 Tumor heterogeneity may have led to the incon sistent findings of morphometric analysis as a prognostic factor. Heterogeneity in ploidy pattern in the tumor was observed in 40% to 50% of cases.5,6 Nuclear shape and chromatin variation in the tumor were of higher predictive value than were absolute data obtained in radical prostatec tomy material.7
To reduce tumor size preoperatively, hormonal pretreatment has been suggested. Neoadjuvant hormonal treatment was shown to reduce the number of positive resection margins and lymph node métastasés 8, 9 The influence on long-term 
MATERIAL AND METHODS
From 1986 to 1992, 56 consecutive radical prostatectomy specimens were obtained. Forty-four patients underwent sur gery w ithout prior horm onal intervention, whereas 12 pa tients were treated with horm onal agents before surgery.
Patient age ranged from 42 to 73 years (median 65). For each patient, preoperative clinical stage was available and was obtained by digital rectal examination (DRE), transrectal ul trasound (TRUS), and sextant prostate biopsies. Moreover, serum prostate-specific antigen (PSA), hemoglobin, and acid phosphatase levels and performance status were documented. Four-to 10-year follow-up data (median 5.1 years) were avail able. PSA recurrence was taken as the end point, and was performed by the Hybritech Tandem-E singlepomt assay; analysis after February 1, 1995 was perform ed with the m ul tipoint assay. All patients reached nadir of PSA value several months after surgery. PSA recurrence was defined as an in crease in serum PSA level of more than 1 ng/mL and 0.04 ng/ mL for the singlepoint and multipoint Hybritech Tandem-E assay, respectively. Hormonal treatment consisted of maximal horm onal blockade with a luteinizing hormone-releasing hor mone (LHRH)-agonist (mostly goserelin) and an antiandro gen (flutamide) for at least 2 months. Radical prostatectomy was performed within 8 weeks after horm onal manipulation.
Material of radical prostatectomy was cut for evaluation of the entire prostate in quarter-prostate sections. Material was routinely processed by fixation in formaldehyde. For embed ding, paraffin was used. After embedding, 4-^m sections were cut. From each block (at least 10 per patient), a liematoxylineosin (HE) and adjacent Feulgen-stained slide was obtained. On the HE-stained slide, all tum or areas were marked by the pathologist. An experienced uropathologist reviewed all HEstained slides and marked each tumor area. Different tumor areas were discriminated based on Gleason grade, m orphol ogy, and individual location. W hen large tum or areas were present with clear variation in Gleason grade, those areas were separately marked and analyzed. In 56 specimens, 349 differ ent tum or areas were detected. For each separate tumor lo cation, we estimated volume by delineating the tumor area and multiplying it by 4 ¡im (section thickness). Subsequent sections were analyzed, and data were sum m ed per tumor area. The marked tum or areas were drawn on the adjacent Feulgen-stained slide, and each tumor area was analyzed by an image analysis system as described previously.10 At least 50 nuclei per tum or area were selected randomly and analyzed for nuclear shape, size, DNA content, and chromatin pattern (Markovian texture) features.10 The system automatically measured all nuclei present in the image. Overlapping nuclei were automatically rejected on the basis of abnormalities in shape. Because segm entation problem s could occur if debris or degenerated nuclei were present in the image, a technician judged every segmented nucleus and rejected incorrectly seg m ented and degenerated nuclei. Autologous leukocytes pres ent on the slide were selected for reference of 2 c for DNA ploidy analysis. Overall analysis of one tum or area required approximately 60 minutes.
W ithin each tumor, the selected tum or areas were com pared. For each tumor, we were able to calculate the highest and lowest value for each nuclear feature per tum or area. Therefore, we defined as a measure for intratum oral hetero geneity the difference betw een the highest and lowest value for nuclear shape, size, and chrom atin pattern. W hen differ ences between tum or areas w ithin a specim en were high, tu mor heterogeneity was considered high, whereas hom ogene ity was defined when only slight differences in nuclear features among different tum or areas w ithin one prostatec tomy specimen were detected. Moreover, ploidy analysis was performed for each tum or area. A neuploidy was defined when a peak in the DNA histogram was present over 2.5 c, which means that no discrimination was m ade between triploidy and tetraploidy. For each tum or, the percentage of aneuploid tu mor foci was calculated.
The m orphom etric and clinical data were com pared with PSA recurrence by multivariate Cox regression analysis using SPSS/PC+ software. The forw ard-conditional m ethod was ap plied with a P value of 0.05 for entry and of 0.10 for removal. To evaluate the influence of neoadjuvant horm onal treatment, we applied the nonparam etric M ann-W hitney 17 test. Table I . Pathologic staging findings are shown in Table II .
RESULTS

Distribution of clinical stage and grade is shown in
The overall PSA recurrence rate was 39.3%. All patients developed pathologic proven recurrence, with increase in serum PSA values. Pathologic stage tended to correlate with PSA recurrence in patients both with and without neoadjuvant treat ment, but this was not statistically significant (Ta ble II).
In a multivariate analysis of clinical and karyometric features, heterogeneity in nuclear shape was the best predictor of pathologic tumor stage. The number of tumor foci per specimen was cor related with the total tumor volume (Pearson, r = 0.69, P = 0.001). Karyometric tumor heteroge neity increased with the number of tumor foci and total tumor volume. Whereas clinical staging was not significantly different between patients with and without hor-treated tumors. In particular, heterogeneity in monal pretreatment, pathologic stages were sig nificantly higher in patients with no previous treatment. Several nuclear features were differ-chromatin pattern ( Fig. 1) and nuclear shape (MPASS, Fig. 2 ) was lower in patients with neoadjuvant hormonal treatment. The maximal ent between hormonally pretreated and nonpre-and minimal values per group are shown in Fig-ures lb and 2b. The length of the bar corre sponds to the difference values as show n in Fig  ures la and 2a . The percentage of aneuploid tum or foci w ithin the tum or was higher in the neoadjuvant group (Fig. 3) . In a univariate Cox regression analysis, several clinical features correlated w ith PSA recurrence in the group w ithout pretreatm ent (Table III) . Of the nuclear features describing heterogeneity, that is, differences w ithin the tum or, heterogeneity in chrom atin pattern (DL2) and nuclear shape (DPASS) were negatively correlated w ith the PSA recurrence-free interval. In the neoadjuvantly treated patients, as for those w ithout pretreatm ent, the PSA recurrence-free interval also tended to de crease w ith an increase in tum or heterogeneity, as assessed by karyometric analysis (Figs. 1, 2) . Be cause only 12 patients were included in this group, no statistical analysis could be performed.
The m ultivariate Cox regression analysis for the prediction of PSA recurrence-free interval in the group w ithout pretreatm ent (n = 44) showed pre operative PSA level and heterogeneity in nuclear shape to be the best predictors (Table IV) .
COMMENT
Prognosis after radical surgery for prostate can cer is dependent on pathologic grade and the status of the resection m argins.11 Local extension of disease decreases recurrence and progressionfree intervals.
N uclear shape, quantitated by image analysis m ethods, was show n by som e investigators to provide prognostic inform ation in addition to tum or stage in low-stage prostate carcinom a.1"3 O thers, however, could n o t confirm the prog nostic value of nuclear shape and propagated variation of nuclear size w ith in the tum or.4 A possible explanation for this discrepancy is that prostate cancers occur m ultifocally in m ost cases. A lthough little is know n about the way in w hich tum ors progress and becom e invasive or m etastasize, genetic instability is assum ed to play an im p o rtan t role in the process. Selecting only the m orphologically m ost atypic tum or area for grading may n o t provide a reflection of the spectrum of m alignant genetic changes that oc cur in the prostate.
For renal carcinoma, nuclear shape and chro m atin changes w ithin the tum or are highly corre lated w ith tum or progression in localized cancer.10 In metastasized renal tum ors, heterogeneity of the prim ary tum or was of no predictive value in prog nosis,10 putatively because in disseminated disease genetic instability has already resulted in a highly m alignant advanced tum or cell line determ ining prognosis. This was confirmed by the finding that No Yes Neoadjuvant treatment in advanced disease prognosis was correlated w ith the absolute values of aberrant nuclear shape and DNA content rather th an w ith intratum oral het erogeneity.10 In p ro state cancer, in tra tu m o ra l heterogeneity was detected for G leason g ra d e ,12 DNA ploidy,5,6 p53 m u ta tio n s,13 and an d ro g en recep to r expres sio n .14 H eterogeneity in n u clear shape and ch ro m atin p attern was sh o w n to correlate w ith local tum or progression.7 M oreover, the coefficient of variation in nuclear size, ra th e r th an the absolute m ean value, correlated w ith survival after radical prostatectom y. 4 In th e p re se n t stu d y , nuclear features correlated w ith PSA recu rren ce after radical prostatectom y. A bsolute m o rp h o lo g y n u clear values w ere less im p o rta n t for predicting progression than was v ariatio n in n u clear char acteristics w ith in the tu m o r. An increase in n u clear polym orphism an d h etero g en eity in ch ro m atin p attern was inversely co rrelated w ith the PSA recurrence-free interval. W e assum e th at ge netic instability causes th e in tra tu m o r differ ences.
N eoadjuvant h o rm o n al tre a tm en t influenced tu m o r heterogeneity. C o m p ariso n of m aterial af ter n eo ad ju v an t tre a tm e n t w ith m aterial from patients treated only w ith su rg ery sh o w ed that the tum ors w ere m u ch sm aller an d less h etero geneous in the form er group. W ith regard to neoadjuvant treatm ent, the p re se n t stu d y was perform ed o n m aterial fro m n o n ran d o m ized studies. C linical tu m o r stage in th e n eo ad ju v an t and n o n -n eo ad ju v an t g ro u p , how ever, was com parable, w hereas p ath o lo g ic stage w as signifi cantly low er in the p a tien ts treated n eo ad ju vantly, suggesting th a t th e h o rm o n a l treatm en t caused so-called " dow ns taging."9 A lthough only Key; DPASSthe difference between the m inim al and maxima! MPASS value of tumor areas within the tum or 12 patients were included in the neoadjuvant group, patients with more heterogeneous tu mors, like the patients who were not pretreated, had a shorter PSA recurrence-free interval. The trend toward an increased percentage of aneuploid cell populations in patients treated neoadjuvantly, despite the decrease in tumor size and nuclear heterogeneity as compared with tumors not pretreated, needs further analysis. This find ing may partly explain the higher PSA recurrence rate of the patients with hormonal pretreatmeni. Patient groups are too small to allow us to draw any conclusions regarding the long-term effects of neoadjuvant treatment on prognosis. Nuclear appearance discloses information re garding tumor malignancy in prostate cancer. To obtain adequate information on prognosis, one should analyze different tumor areas to estimate intratumoral heterogeneity. Because nuclear morphometric analysis is a time-consuming proce dure, it cannot yet replace visual tumor grading. Neoadjuvant hormonal treatment appears to re duce intratumoral heterogeneity. In this small population, such reduction was not correlated with improved prognosis. The finding of increased aneuploidy in patients treated neoadjuvantly is also of interest.
